Canton Strategic Holdings (CNTN) Interest Expenses (2021 - 2025)
Canton Strategic Holdings posted quarterly Interest Expenses of $4065.0 for Q4 2025, up 436.28% year-on-year from $758.0 in Q4 2024, and down 57.87% on a QoQ basis from $9648.0 in Q3 2025.
Canton Strategic Holdings (CNTN) has 5 years of Interest Expenses data on file, last reported at $4065.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses rose 436.28% year-over-year to $4065.0; the trailing twelve-month figure through Mar 2026 stood at $19874.0 (up 13.86% YoY), and the FY2025 full-year result was $28345.0, up 107.14% from the prior year.
- Interest Expenses for Q4 2025 stood at $4065.0, down from $9648.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1.6 million in Q1 2022 and bottomed at -$8756.0 in Q4 2022.
- The 5-year median for Interest Expenses is $6149.5 (2023), against an average of $137826.0.
- Peak annual rise in Interest Expenses reached 979.69% in 2022, while the deepest fall reached 103.39% in 2022.
- A 5-year view of Interest Expenses shows it stood at $258000.0 in 2021, then tumbled by 103.39% to -$8756.0 in 2022, then soared by 104.04% to $354.0 in 2023, then soared by 114.12% to $758.0 in 2024, then soared by 436.28% to $4065.0 in 2025.
- The last three Interest Expenses figures came in at $4065.0 (Q4 2025), $9648.0 (Q3 2025), and $6161.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,065.00 |
| Dec 31, 2025 | 4,065.00 |
| Sep 30, 2025 | 9,648.00 |
| Sep 30, 2025 | 9,648.00 |
| Jun 30, 2025 | 6,161.00 |
| Jun 30, 2025 | 6,161.00 |
| Mar 31, 2025 | 8,471.00 |
| Mar 31, 2025 | 8,471.00 |
| Dec 31, 2024 | 758.00 |
| Dec 31, 2024 | 758.00 |
| Sep 30, 2024 | 3,009.00 |
| Sep 30, 2024 | 3,009.00 |
| Jun 30, 2024 | 5,217.00 |
| Jun 30, 2024 | 5,217.00 |
| Mar 31, 2024 | 4,700.00 |
| Mar 31, 2024 | 4,700.00 |
| Dec 31, 2023 | 354.00 |
| Dec 31, 2023 | 354.00 |
| Sep 30, 2023 | 3,496.00 |
| Sep 30, 2023 | 3,496.00 |
| Jun 30, 2023 | 6,517.00 |
| Jun 30, 2023 | 6,517.00 |
| Mar 31, 2023 | 6,138.00 |
| Mar 31, 2023 | 6,138.00 |
| Dec 31, 2022 | -8,756.00 |
| Dec 31, 2022 | -8,756.00 |
| Mar 31, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Dec 31, 2021 | 258,000.00 |
| Dec 31, 2021 | 258,000.00 |
| Sep 30, 2021 | 236,000.00 |
| Sep 30, 2021 | 236,000.00 |
| Jun 30, 2021 | 188,900.00 |
| Jun 30, 2021 | 188,900.00 |
| Mar 31, 2021 | 148,190.00 |
| Mar 31, 2021 | 148,190.00 |